Conformation-dependent binding and tumor-targeted delivery of siRNA by a designed TRBP2: Affibody fusion protein

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 6, 2015, Pages 1455-1466

  Dar, Ghulam Hassan ^a   Gopal, Vijaya ^a   Rao, Madhusudhana ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

Affibody; Epidermal growth factor receptor 2; Fusion proteins; siRNA delivery; TRBP2; Tumor targeting

Indexed keywords

BIOLOGICAL MATERIALS; CELL PROLIFERATION; DISEASES; GENES; ONCOLOGY; PROTEINS; RNA; TUMORS;

AFFIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUSION PROTEINS; SIRNA DELIVERY; TRBP2; TUMOR TARGETING;

GENE THERAPY;

AURORA B KINASE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYBRID PROTEIN; INTERLEUKIN 6; MESSENGER RNA; NANOCARRIER; PROSTAGLANDIN SYNTHASE; PROTEIN P53; SMALL INTERFERING RNA; TRANSACTIVATION RESPONSE RNA BINDING PROTEIN 2 EPIDERMAL GROWTH FACTOR RECEPTOR 2 BINDING AFFIBODY FUSION PROTEIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AURKB PROTEIN, MOUSE; RNA BINDING PROTEIN; TRANS-ACTIVATION RESPONSIVE RNA-BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; ENDOCYTOSIS; ENDOSOME; ENTHALPY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; INNATE IMMUNITY; INTERNALIZATION; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; PROTEIN STABILITY; RNA CONFORMATION; RNA DEGRADATION; STOICHIOMETRY; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; GENETICS; HUMAN; PROTO ONCOGENE; TUMOR CELL LINE;

ANIMALS; AURORA KINASE B; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE SILENCING; GENES, ERBB-2; HUMANS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937136212     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.01.017     Document Type: Article

References (51)

1. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173-184.
2. Kanasty R.L., Whitehead K.A., Vegas A.J., Anderson D.G. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther 2012, 20:513-524.
3. Wheeler L.A., Vrbanac V., Trifonova R., Brehm M.A., Gilboa-Geffen A., Tanno S., et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther 2013, 21:1378-1389.
4. Bedi D., Musacchio T., Fagbohun O.A., Gillespie J.W., Deinnocentes P., Bird R.C., et al. Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. Nanomedicine 2011, 7:315-323.
5. Que-Gewirth N.S., Sullenger B.A. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007, 14:283-291.
6. Wu S.Y., McMillan N.A. Lipidic systems for in vivo siRNA delivery. AAPS J 2009, 11:639-652.
7. Craik D.J., Fairlie D.P., Liras S., Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013, 81:136-147.
8. Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther Deliv 2011, 2:891-905.
9. Mendonca L.S., Firmino F., Moreira J.N., Pedroso de Lima M.C., Simoes S. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 2010, 21:157-168.
10. Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A 2010, 107:15039-15044.
11. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23:709-717.
12. Peer D., Zhu P., Carman C.V., Lieberman J., Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 2007, 104:4095-4100.
13. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
14. Geoghegan J.C., Gilmore B.L., Davidson B.L. Gene silencing mediated by siRNA-binding fusion proteins is attenuated by double-stranded RNA-binding domain structure. Mol Ther Nucleic Acids 2012, 1:e53.
15. Fiedel B.A., Rent R., Myhrman R., Gewurz H. Complement activation by interaction of polyanions and polycations. Immunology 1976, 30:161-169.
16. Van Asbeck A.H., Beyerle A., McNeill H., Bovee-Geurts P.H., Lindberg S., Verdurmen W.P., et al. Molecular parameters of siRNA-cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano 2013, 7:3797-3807.
17. Jarver P., Coursindel T., Andaloussi S.E., Godfrey C., Wood M.J., Gait M.J. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids 2012, 1:e27.
18. Schneider B., Grote M., John M., Haas A., Bramlage B., Ickenstein L.M., et al. Targeted siRNA delivery and mRNA knockdown mediated by bispecific digoxigenin-binding antibodies. Mol Ther Nucleic Acids 2012, 1:e46.
19. Lunde B.M., Moore C., Varani G. RNA-binding proteins: modular design for efficient function. Nat Rev Mol Cell Biol 2007, 8:479-490.
20. Tian B., Bevilacqua P.C., Diegelman-Parente A., Mathews M.B. The double-stranded-RNA-binding motif: interference and much more. Nat Rev Mol Cell Biol 2004, 5:1013-1023.
21. Eguchi A., Meade B.R., Chang Y.C., Fredrickson C.T., Willert K., Puri N., et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009, 27:567-571.
22. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 2012, 4:130ra48.
23. Gomes-da-Silva L.C., Fonseca N.A., Moura V., Pedroso de Lima M.C., Simoes S., Moreira J.N. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 2012, 45:1163-1171.
24. Hatakeyama H., Akita H., Ito E., Hayashi Y., Oishi M., Nagasaki Y., et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 2011, 32:4306-4316.
25. Daniels S.M., Gatignol A. The multiple functions of TRBP, at the hub of cell responses to viruses, stress, and cancer. Microbiol Mol Biol Rev 2012, 76:652-666.
26. Parker G.S., Maity T.S., Bass B.L. dsRNA binding properties of RDE-4 and TRBP reflect their distinct roles in RNAi. J Mol Biol 2008, 384:967-979.
27. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Hoiden-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
28. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
29. Reichelt P., Schwarz C., Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif 2006, 46:483-488.
30. Greenfield N.J. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 2006, 1:2876-2890.
31. Ryter J.M., Schultz S.C. Molecular basis of double-stranded RNA-protein interactions: structure of a dsRNA-binding domain complexed with dsRNA. EMBO J 1998, 17:7505-7513.
32. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001, 3:802-808.
33. Huynh K.K., Eskelinen E.L., Scott C.C., Malevanets A., Saftig P., Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J 2007, 26:313-324.
34. Eskelinen E.L., Tanaka Y., Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003, 13:137-145.
35. Lidke D.S., Nagy P., Heintzmann R., Arndt-Jovin D.J., Post J.N., Grecco H.E., et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 2004, 22:198-203.
36. Xu Y.M., Wang L.F., Jia L.T., Qiu X.C., Zhao J., Yu C.J., et al. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol 2004, 173:61-67.
37. Rao J., Dragulescu-Andrasi A., Yao H. Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol 2007, 18:17-25.
38. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl. 2):1-13.
39. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
40. Faltus T., Yuan J., Zimmer B., Kramer A., Loibl S., Kaufmann M., et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004, 6:786-795.
41. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004, 4:927-936.
42. Addepalli M.K., Ray K.B., Kumar B., Ramnath R.L., Chile S., Rao H. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther 2010, 17:352-359.
43. Simpson K.J., Selfors L.M., Bui J., Reynolds A., Leake D., Khvorova A., et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol 2008, 10:1027-1038.
44. Robbins M., Judge A., MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009, 19:89-102.
45. Yamashita S., Nagata T., Kawazoe M., Takemoto C., Kigawa T., Guntert P., et al. Structures of the first and second double-stranded RNA-binding domains of human TAR RNA-binding protein. Protein Sci 2011, 20:118-130.
46. Ferrer-Miralles N., Corchero J.L., Kumar P., Cedano J.A., Gupta K.C., Villaverde A., et al. Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact 2011, 10:101.
47. Lo S.L., Wang S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 2008, 29:2408-2414.
48. Midoux P., Kichler A., Boutin V., Maurizot J.C., Monsigny M. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem 1998, 9:260-267.
49. Chang K.L., Higuchi Y., Kawakami S., Yamashita F., Hashida M. Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. Bioconjug Chem 2010, 21:1087-1095.
50. Chauhan V.P., Stylianopoulos T., Martin J.D., Popovic Z., Chen O., Kamoun W.S., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012, 7:383-388.
51. Govindarajan S., Sivakumar J., Garimidi P., Rangaraj N., Kumar J.M., Rao N.M., et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Biomaterials 2012, 33:2570-2582.